New Pill Beats Statins for Cholesterol

An experimental pill named enlicitide has demonstrated a remarkable ability to reduce high LDL cholesterol levels in patients at elevated risk for heart attacks, even when they are already undergoing statin therapy. This novel medication aids the body in clearing cholesterol through a mechanism distinct from statins, offering a potentially more convenient oral option compared to existing injectable treatments.

In a large-scale study involving over 2,900 high-risk patients, those who took a daily enlicitide pill alongside their standard treatment experienced up to a 60% decrease in LDL cholesterol within six months. This significant reduction was sustained over a year with no adverse safety findings compared to the placebo group.

Statins are foundational in cholesterol management by limiting liver production, but many patients require additional intervention. While powerful PCSK9 inhibitor injections exist, their uptake is limited due to administration complexity and cost. Enlicitide aims to bridge this gap.

Merck has sponsored the research and is pursuing expedited FDA review for enlicitide. Although the pill's ability to lower cholesterol is compelling, further studies are underway to confirm if this reduction translates into fewer heart attacks, strokes, and deaths.